Weekly Research Analysts’ Ratings Changes for Centene (CNC)

A number of research firms have changed their ratings and price targets for Centene (NYSE: CNC):

• 2/9/2026 – Centene had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $41.00 price target on the stock.
• 2/7/2026 – Centene was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/22/2026 – Centene had its price target raised by analysts at JPMorgan Chase & Co. from $38.00 to $45.00. They now have a “neutral” rating on the stock.
• 1/21/2026 – Centene had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 1/9/2026 – Centene was given a new $47.00 price target on by analysts at Mizuho.
• 1/7/2026 – Centene was given a new $43.00 price target on by analysts at Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 1/6/2026 – Centene had its “outperform” rating reaffirmed by analysts at Sanford C. Bernstein. They now have a $59.00 price target on the stock.
• 1/5/2026 – Centene had its price target raised by analysts at Truist Financial Corporation from $45.00 to $47.00. They now have a “buy” rating on the stock.
• 12/11/2025 – Centene had its price target raised by analysts at Robert W. Baird from $28.00 to $36.00. They now have a “neutral” rating on the stock.

Centene Corporation (NYSE: CNC) is a diversified, multi-national healthcare enterprise that specializes in providing services to government-sponsored and national health programs. The company primarily acts as a managed care organization, delivering healthcare coverage and administering benefits for Medicaid, the Children’s Health Insurance Program (CHIP), Medicare Advantage, and individual marketplace plans. Centene also contracts with federal and state agencies to manage specialty care programs and community-based services for vulnerable populations.

Centene’s offerings extend beyond traditional insurance to include a range of specialty and support services.